1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Implanet SA

Implanet SA

0.15
EUR
0.00
(0.00%)
29.20MMarket Cap
Mar 09Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
82.7
52.14
27.46
16.88
13.48
9
6.24
1.92
0.72
0.39
0.19
0.07
0.1
- -
Basic EPS, GAAP
-84.59
-50.91
-33.05
-15.72
-11.37
-7.43
-3.07
-1.27
-0.36
-0.17
-0.17
-0.03
-0.03
- -
Free Cash Flow per Basic Share
-72.18
-46.1
-29.34
-13.82
-8.34
-6.39
-2.5
-1.04
-0.42
-0.13
-0.04
-0.02
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
103.18
53.93
36.99
18.25
9.17
2.83
0.84
0.19
0.21
0.11
- -
0.01
- -
- -
Tangible Book Value per Share
98.08
49.28
34.58
17.32
8.14
1.83
0.17
0.03
-0.21
-0.05
-0.08
-0.02
-0.02
-0.02
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
1
3
9
21
39
127
128
129
Sales/Revenue/Turnover
7
7
7
8
8
7
7
6
6
8
7
9
12
- -
Operating Margin (%)
-93.18
-94.44
-118.52
-86.04
-73.37
-71.99
-50.16
-52.05
-77.87
-52.14
-58.69
-51.17
-31.49
- -
Depreciation Expense
2
1
1
1
1
1
1
-1
-1
-1
-1
-1
-1
- -
Net Income, GAAP
-7
-7
-8
-7
-7
-6
-4
-4
-3
-4
-7
-4
-4
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-102.29
-97.63
-120.35
-93.14
-84.33
-82.6
-49.21
-66.13
-50.29
-44.1
-89.65
-46.42
-35.13
- -
Working Capital
6
3
8
7
5
1
1
2
1
- -
-3
-2
-3
-3
LT Debt
3
2
2
1
1
1
2
3
6
3
2
2
1
1
Total Equity
14
7
10
10
6
2
1
1
3
4
- -
1
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-73.79
-65.19
-94.54
-75.19
-82.92
-127.74
-189.89
-323.52
-161.42
-111.58
- -
- -
-774.89
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
4
5
5
LT Borrowings
1
1
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
125
125
144
Market Capitalization
14
12
29

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
10
12
14
Cash, Cash Equivalents & STI
2
1
3
Accounts Receivable, Net
2
3
3
Inventories
6
8
7
Total Current Liabilities
12
16
17
Payables & Accruals
- -
- -
- -
ST Debt
4
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-63.29%
-93.3%
-44.43%
Free Cash Flow
-9.47%
-6.09%
-34.14%
Net Income, GAAP
-1.29%
9.33%
0.37%
Sales/Revenue/Turnover
7.95%
16.91%
32.62%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
7
2024
- -
- -
9
2025
- -
- -
12

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.17
2024
- -
- -
-0.03
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ludovic Lastennet
Full Time Employees
49
Sector
Health technology
Industry
Medical specialties
Address
Technopole Bordeaux Montesquieu Martillac NA France 33650
IPO Date
Nov 25, 2013
Website
implanet.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Implanet S.A. designs, manufactures and markets medical implants and instruments for orthopedic surgery, with a primary focus on spine surgery solutions including its flagship JAZZ platform of latest-generation vertebral fusion implants, thoraco-lumbar screws, intersomatic cages and cervical plates; knee surgery products such as the MADISON prosthetic knee implant and arthroscopy devices; and complementary offerings like ultrasonic osteotomy systems, suture threads, anchors, pins, screws and spinal bracing systems. The company, founded in 2006 and headquartered in Martillac near Bordeaux, France, operates internationally through direct sales in key markets including France, the United States, Germany and Brazil, as well as distributors across Europe, the Middle East, Africa, Latin America and Asia-Pacific, including recent expansion of the JAZZ platform into China. Subsidiaries and group companies include Orthopaedic & Spine Development (OSD), acquired in May 2021 to bolster its reconstructive orthopedics portfolio with manufacturing in Avrillé, France. In recent developments, Implanet reported first-half 2025 revenue growth of 41% to €5.81 million, driven by accelerated commercial momentum, product innovation and strengthened investments in the United States; signed an exclusive distribution agreement with TINAVI Medical Technologies for the TiRobot spine surgery system and a partnership with 8i Robotics Inc. in November 2025 for clinical evaluation of a surgeon-supervised robotic system; continued its strategic collaboration with Sanyou Medical, China's second-largest medical device maker, encompassing commercial, technological and financial ties initiated in 2022 with a €5 million capital commitment in 2023-2024; and secured approximately €2 million in financing in late 2024 to support operational needs and growth projections into 2025.